536 related articles for article (PubMed ID: 33524008)
21. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
22. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
[TBL] [Abstract][Full Text] [Related]
23. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638
[TBL] [Abstract][Full Text] [Related]
24. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
25. Effects of Dahuang zhechong pill on doxorubicin-resistant SMMC-7721 xenografts in mice.
Wu L; Cao KX; Ni ZH; Li WD; Chen ZP; Cheng HB; Liu X
J Ethnopharmacol; 2018 Aug; 222():71-78. PubMed ID: 29609009
[TBL] [Abstract][Full Text] [Related]
26. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
[TBL] [Abstract][Full Text] [Related]
27. [Preparation of doxorubicin encapsulated in amphiphilic polysaccharide nanoparticles and anti-hepatocarcinoma effect thereof].
Huang YF; Gu WL; Li ZH; Chen RF; Zhou JJ; Zhou QB; Guo N
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):810-2. PubMed ID: 19595118
[TBL] [Abstract][Full Text] [Related]
28. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
29. Self-Assembling Doxorubicin Prodrug Forming Nanoparticles and Effectively Reversing Drug Resistance In Vitro and In Vivo.
Mao X; Si J; Huang Q; Sun X; Zhang Q; Shen Y; Tang J; Liu X; Sui M
Adv Healthc Mater; 2016 Oct; 5(19):2517-2527. PubMed ID: 27529558
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines.
Wang J; Chan JY; Fong CC; Tzang CH; Fung KP; Yang M
Liver Int; 2009 Oct; 29(9):1338-47. PubMed ID: 19627484
[TBL] [Abstract][Full Text] [Related]
31. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
33. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
34. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
35. Co-delivery of Poria cocos extract and doxorubicin as an 'all-in-one' nanocarrier to combat breast cancer multidrug resistance during chemotherapy.
Li Y; Li X; Lu Y; Chaurasiya B; Mi G; Shi D; Chen D; Webster TJ; Tu J; Shen Y
Nanomedicine; 2020 Jan; 23():102095. PubMed ID: 31669856
[TBL] [Abstract][Full Text] [Related]
36. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
37. Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer.
Han NN; Li X; Tao L; Zhou Q
Biochem Biophys Res Commun; 2018 Mar; 498(1):178-185. PubMed ID: 29317204
[TBL] [Abstract][Full Text] [Related]
38. Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles.
Yang S; Zhang B; Zhao X; Zhang M; Zhang M; Cui L; Zhang L
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791591
[TBL] [Abstract][Full Text] [Related]
39. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells.
Wang J; Li N; Cao L; Gao C; Zhang Y; Shuai Q; Xie J; Luo K; Yang J; Gu Z
J Mater Chem B; 2020 Feb; 8(6):1157-1170. PubMed ID: 31951231
[TBL] [Abstract][Full Text] [Related]
40. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
